[1] Altman, D.G. (1991) Practical Statistics for Medical Research. Chapman and Hall, London.

[2] Maughan, T.S., James, R.D., Kerr, D.J., Ledermann, J.A., McArdle, C., Seymour M.T., Cohen, D., Hopwood, P., Johnston, C., and Stephens, R.J. for the British MRC Colorectal Cancer Working Party. (2002) Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet, 359, 1555-63.

[3] International collaboration of trialists. (1999) Adjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet, 354, 533-40.

[4] TheICON2 Collaborators. (1998) Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet, 352, 1571-6.

[5] Saunders, M., Dische, S., Barrett, A., Harvey, A., Gibson, D., and Parmar, M. (1997) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomized multicentre trial. Lancet, 350, 161-5.

[6] Bland, M. (1987) An Introduction to Medical Statistics. Oxford University Press, Oxford.

[7] Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., and Howard, S.V. (1976) Design and analysis of randomised controlled trials requiring prolonged observation of each patient. I. Introduction and design. British Journal of Cancer, 34, 585-612.

[8] Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., and Howard, S.V. (1976) Design and analysis of randomised controlled trials requiring prolonged observation of each patient. II. Analysis and examples. British Journal ofCancer, 35, 1-39.

[9] Parmar, M.K.B., and Machin, D. (1995) Survival Analysis: A Practical Approach. John Wiley, New York.

[10] Thatcher, N., Girling, D.J., Hopwood, P., Sambrook, R.J., Qian, W.D., and Stephens, R.J. (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicenter randomized trial. Journal of Clinical Oncology, 18, 395-404.

[11] Senn,S.J. (1989) Covariate imbalance and random allocation in clinical trials. Statistics in Medicine, 8, 467-75.

[12] Early Breast Cancer Trialists Collaborative Group. (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet, 355, 1757-70.

[13] Collins, R., Gray, R., Godwin, J., and Peto, R. (1987) Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Statistics in Medicine, 6, 245-50.

[14] Tierney, J.F., Stewart, L.A., Parmar, M.K.B., Fletcher, C.D.M., Jones, G., Mosseri, V., Patel, M., de Elvira, M.C.R., Souhami, R.L., Sylvester, R., Tursz, T., Alvegard, T.A., Sigurdsson, H., Antman, K., Bacchi, M., Baker, L.H., Benjamin, R.S., Brady, M.F., Bramwell, V., Bui, B.N., Edmonson, J.H., Leyvraz, S., Omura, G.A., Rouesse, J., Ryan, L., van Oosterom, A.T., and Yang, J.C. (1997) Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet, 350, 1647-54.

[16] Fayers, P.M.F. Scoring manual for the EORTC QLQ-C30.

[17] Hopwood, P., Harvey, A., Davies, J., Stephens, R.J., Girling, D.J., Gibson, D., and Parmar, M.K.B. (1998) Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. European Journal of Cancer, 34, 49-57.

[18] Fayers, P.M., Curran, D., and Machin, D. (1998) Incomplete quality of life data in randomized trials: missing items. Statistics in Medicine, 17, 679-96.

[19] Qian, W., Parmar, M.K.B., Sambrook, R.J., Fayers, P.M., Girling, D.J., and Stephens, R.J. (2000) Analysis of messy longitudinal data from a randomized clinical trial. Statistics in Medicine, 19, 2657-74.

[20] Hollen, P.J., Gralla, R.J., Cox, C., Eberly, S.W., and Kris, M.G. (1997) A dilemma in analysis: issues in the serial measurement of quality of life in pateints with advanced lung cancer. Lung Cancer, 18, 119-36.

[21] Machin, D., and Weeden, S. (1998) Suggestions for the presentation of quality of life data from clinical trials. Statistics in Medicine, 17, 711-24.

[22] Bailey, A.J., Parmar, M.K.B., Stephens, R.J. on behalf of the CHART Steering Committee. (1998) Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated acclerated radiotherapy (CHART) randomized trial in non-small-cell lung cancer. Journal of Clinical Oncology, 16, 3082-93.

[23] Curran, D., Aaronson, N., Standaert, B., Molenberghs, G., Therasse, P., Ramirez, A., Koopman-schap, M., Erder, H., and Piccart, M. (2000) Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. European Journal ofCancer, 36, 834-44.

[24] Matthews, J.N.S., Altman, D.G., Campbell, M.J., and Royston, P. (1990) Analysis of serial measurements in medical research. British Medical Journal, 300, 230-5.

[25] Little, J.M. (1987) A method of calculating the value of palliative care of cancer patients. Australian, New Zealand Journal of Surgery, 57, 393-7.

[26] Lindsey, J.K. (1999) Models for Repeated Measurements (2nd ed.). Oxford University Press, New York.

[27] Osoba, D., Rodrigues, G., Myles, J., Zee, B., and Pater, J. (1998) Intrepreting the significance of changes in health related quality of life scores. Journal of Clinical Oncology, 16, 139-44.

[28] King, M.T. (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5, 555-67.

[29] Kaplan, R.M. (1993) Quality of life assessment for cost/utility studies in cancer. Cancer Treatment Reviews, 19 (supp A) 85-96.

[30] Olschewski, M., and Schumacher, M. (1990) Statistical analysis of quality of life data in cancer clinical trials. Statistics in Medicine, 9, 749-63.

[31] Gelber, R.D., and Goldhirsch, A. (1986) A new endpoint for the assessment of adjuvant therapy in post-menopausal women with operable breast cancer. Journal of Clinical Oncology, 4, 1772-9.

[32] Feldstein, M.L. (1991) Quality of life adjusted survival for comparing cancer treatments; a commentary on TWIST and Q-TWIST. Cancer, 67, 851-4.

[33] Goldhirsch, A., Gelber, R.D., Simes, R., Goldhirsch, A., Gelber, R.D., Simes, R., Glasziou, P., and Coates, A.S. (1989) Cost and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. Journal of Clinical Oncology, 36-44.

[34] Parmer, M.K.B., Griffiths, G.O., Spiegelhalter, D.J., Altman, D., and Souhami, R.L. On behalf of the CHART Steering Committee. Monitoring of large randomised clinical trials: a new apprroach with Bayesian methods. (2001) Lancet, 358, 375-81.

[35] Pocock, S.J. (1982) Interim analysis for randomized clinical trials: the group sequential approach. Biometrics, 38, 153-62.

[36] McPherson, K. (1982) On choosing the number of interim analyses in clinical trials. Statistics in Medicine, 1, 25-36.

[37] O'Brien, P.C., and Fleming, T.R. (1979) A multiple testing procedure for clinical trials. Biometrics, 35, 549-56.

[38] De Mets, D.I., and Lan, K.K.G. (1994) Interim analysis: the alpha spending function approach. Statistics in Medicine, 13, 1341-52.

[39] Todd, S., and Whitehead, J. (1996) Point and interval estimation following a sequential clinical trial. Biometrika, 83, 453-61.

[40] Dillman, R.O., Seagren, S.L., Propert, K.J., Guerra, J., Eaton, W.L., Perry, M.C., Carey, R.W., Frei, E.F., and Green, M.R. (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage-iii non-small-cell lung cancer. New England Journal of Medicine, 323, 940-45.

[41] Souhami, R.L., Spiro, S.G., and Cullen, M. (1991) Chemotherapy and radiation-therapy as compared with radiation-therapy in stage III non-small-cell cancer. New England Journal ofMedicine, 324, 1136.

[42] Sylvester, R., Bartelink, H., and Rubens, R. (1994) A reversal of fortune: practical problems in the monitoring and interpretation of an EORTC breast cancer trial. Statistics in Medicine, 13,1329-35.

[43] Berntsen, R.F., Rasmussen, K., and Bjornstad, J.F. (1991) Monitoring a randomized clinical-trial for futility - the North-Norwegian Lidocaine Intervention Trial. Statistics In Medicine, 10, 405-12.

[44] De Mets, D.L., Pocock, S.J., and Julian, D.G. (1991) The agonising negative trend in monitoring of clinical trials. Lancet, 354, 1983-88.

Smoking Solutions

Smoking Solutions

How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution. Get All The Support And Guidance You Need To Be A Success At Quitting Smoking. This Book Is One Of The Most Valuable Resources In The World When It Comes To How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution.

Get My Free Ebook

Post a comment